Jun 06,2022

Diabetes Reversal Leader Virta Health Showcases Transformative, Long-Lasting Cardiometabolic Health Improvements for Veteran Patients

Today, Virta Health, the type 2 diabetes reversal leader, announced two-year patient outcomes from its multi-year partnership with the Department of Veterans Affairs (VA). The results, presented at the American Diabetes Association 82nd Scientific Sessions, highlight broad metabolic health improvements for Veteran patients, including long-term blood sugar reduction, clinically-significant weight loss, and medication deprescription.

CLINICAL STUDY

#rwe

View Analyst & Ambassador Comments
Go to original news
Jun 14,2022

Pear Therapeutics Announces New 12-Month Analysis Showing Reduction In Healthcare Resource Utilization And Associated Costs In Patients Treated With Reset-O®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced a manuscript accepted for publication and available via pre-print of a real-world study demonstrating reduced health care resource utilization and associated costs for reSET-O®, the only FDA-authorized PDT for the treatment of opioid use disorder (OUD).

CLINICAL STUDY

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 15,2022

Akili’s digital therapeutic tech improves cognitive function in lupus patients: study

A recently published study found that Akili’s AKL-T01 program—which was cleared by the FDA in 2020 under the product name EndeavorRx to improve attention function in children with attention-deficit/hyperactivity disorder (ADHD)—can also be successfully used by adults with systemic lupus erythematosus to boost cognitive function.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Jul 19,2022

New Study Links One Drop's AI-Powered Blood Glucose Forecasts to Better Engagement and Diabetes Outcomes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, today announced outcomes from a retrospective cohort study published in the Journal of Medical Internet Research (JMIR) on the effects of its novel AI-powered blood glucose (BG) forecasting feature. The study focuses on indicators of glycemic control and health data logging in adults with type 2 diabetes (T2Ds) using the award-winning One Drop digital health platform.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 01,2022

PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company noted that its Founded Entity, Akili Interactive Labs, Inc. (“Akili”), a leading digital medicine company, today announced the start of a pivotal Phase 3 randomized, controlled study of SDT-001 (a version of AKL-T01 localized for Japanese language and culture), a product candidate designed to improve measures of attention in children diagnosed with attention-deficit/hyperactivity disorder (“ADHD”). The study, conducted by Akili’s partner, global pharmaceutical company Shionogi & Co., Ltd. (“Shionogi”), is designed to evaluate the safety and efficacy of the product candidate in children ages 6-17 with ADHD as a registration-enabling trial. Clinical trial sites have begun enrolling patients, and results of the study are expected in 2H2023.

CLINICAL STUDY

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 01,2022

Cognito’s light-and-sound therapy slows brain tissue atrophy in Alzheimer’s study

After demonstrating last year that its light- and sound-based therapy could help improve memory and cognition among Alzheimer’s patients in an early clinical study, Cognito Therapeutics is going a step deeper. It has new data showing that six months’ use of its digital therapeutic could potentially reduce the rate of atrophy within the brain's white matter. In the phase 2 study, named Overture, participants wore the company’s GammaSense headset at home for one hour per day for six months. Cognito’s analysis compared participants treated in the Overture study, which enrolled 76 people, to historical data collected from a separate, decade-long, global study conducted by the Alzheimer’s Disease Neuroimaging Institute.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Aug 03,2022

Kaia Health Reduces Back Pain by 46% in Rise-uP Randomized Controlled Trial Results

Kaia Health, the largest global digital therapeutics company on a mission to make high-quality, evidence-based therapies accessible to anyone, anytime, today announced results from the Rise-uP randomized controlled trial, which demonstrated that the use of digital multimodal therapy leads to a significant reduction in back pain. After the 12-month trial period, study participants who engaged with the Kaia Health app experienced a 46% percent reduction in pain and significant improvements in functional capacity and mental and physical quality of life metrics.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 10,2022

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the publication of new results from a health economic analysis of real-world data to evaluate healthcare resource utilization, associated costs and insomnia severity for Somryst® (previously known as SHUTi in its prior incarnation), the only FDA-authorized PDT for the treatment of chronic insomnia. The analysis evaluated real-world data of 248 adult patients with chronic insomnia treated with Somryst over 24-months compared to the 24-months months prior to treatment and found: Reductions in health-related services; An estimated $2,059 reduction in per-patient costs; 37.2% reduction in mean insomnia severity index (ISI) score (19.1 at baseline and 12.0 at nine weeks).

CLINICAL STUDY

#pdt

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 26,2022

One Drop Improves Workplace Productivity for Older Adults with Type 2 Diabetes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, today announced analyses from a randomized control trial (RCT) on the impact of its award-winning digital health platform on workplace productivity (presenteeism) among people with type 2 diabetes published in the Journal of Occupational Environmental Medicine (JOEM). Employees using One Drop experienced significant productivity and functioning gains and were less likely to experience presenteeism at follow-up compared to control groups.

CLINICAL STUDY

#connected device

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 05,2022

Results presented at ESMO 2022: Kaiku Health digital patient monitoring platform can help in resolving acute fever in melanoma patients

A multicenter study led by the Netherlands Cancer Institute used Kaiku Health digital patient management platform to investigate the use of digital patient monitoring and support of patients with advanced melanoma. The results published at ESMO 2022 annual conference suggest that Kaiku Health can be used to support patients and to collect real-world evidence. They can also help to understand the development of symptoms and quality of life of the patients.

CLINICAL STUDY

#rwe

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY